Skip to main content
. 2026 Oct 14;17:1903348. doi: 10.3389/fneur.2026.1903348

Figure 3.

Flowchart graphic comparing neurologic workflows for CAR T-cell therapy versus CD3-engaging bispecific antibodies, detailing four sequential steps for each therapy: CAR T-cell therapy includes infusion or admission, early peak-risk window, triggered escalation, and extended BCMA surveillance; CD3-engaging bispecific antibodies include step-up dosing and early cycles, outpatient safety layer, symptom-driven reassessment, and program-level mitigation.

Conceptual timing differences that shape neurologic surveillance. Timing is product- and patient dependent; the figure is not a fixed dosing calendar.